> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Saxenda Label Update on CV Risk
- URL: https://www.fdaweb.com/fda-approves-saxenda-label-update-on-cv-risk/
- Published: 2018-10-24T12:00:00.000Z
- Updated: 2026-09-15T00:40:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142658

FDA has approved an updated label for Novo Nordisk’s weight management drug Saxenda (liraglutide) injection 3 mg to add data from the LEADER trial showing that liraglutide 1.8 mg in another product did not increase the risk of major cardiovascular (CV) events in adults with Type 2 diabetes and established CV disease.

The company says Saxenda is an injectable prescription medicine that may help some adults with excess weight who also have weight-related medical problems or obesity lose weight and keep it off. It should be used with a reduced calorie meal plan and increased physical activity and is not indicated for treating Type 2 diabetes.